During a panel discussion at the Behavioral Health Tech conference, experts shared the promise psychedelic medicines hold for mental health and why employers may want to consider offering them as a workplace benefit.
Psychedelic-assisted therapy is currently used to treat severe mental health conditions. But there is evidence it could help with prevention as well, and more research needs to be done on this, said Sherry Rais, CEO and co-founder of Enthea.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Despite ketamine-assisted therapy being approved for treating several mental health conditions, it's generally not covered by insurance or employers. Though that likely won't always be the case, as psychedelics gather more research and employers notice the benefits for their workplaces.
Enthea, a benefit plan administrator, works with self-insured employers to provide insurance coverage for psychedelic-assisted therapy. The company has gained $2 million in seed funding, led by Tabula Rasa Ventures. With the money, it is planning a nationwide rollout.